CN114984039A - Pharmaceutical composition for chronic wound healing and application thereof - Google Patents

Pharmaceutical composition for chronic wound healing and application thereof Download PDF

Info

Publication number
CN114984039A
CN114984039A CN202210587089.0A CN202210587089A CN114984039A CN 114984039 A CN114984039 A CN 114984039A CN 202210587089 A CN202210587089 A CN 202210587089A CN 114984039 A CN114984039 A CN 114984039A
Authority
CN
China
Prior art keywords
pharmaceutical composition
wound healing
chronic wound
chronic
oral ulcer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210587089.0A
Other languages
Chinese (zh)
Inventor
李向党
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongguan Tangde Medical Technology Co ltd
Original Assignee
Dongguan Tangde Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Tangde Medical Technology Co ltd filed Critical Dongguan Tangde Medical Technology Co ltd
Priority to CN202210587089.0A priority Critical patent/CN114984039A/en
Publication of CN114984039A publication Critical patent/CN114984039A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a pharmaceutical composition for chronic wound healing and application thereof, and belongs to the technical field of medical products, wherein the pharmaceutical composition for chronic wound healing comprises 25-35% of sulfuric acid, 30-55% of hydroxybenzenesulfonic acid and the balance of water in percentage by mass, and the pharmaceutical composition for chronic wound healing can be used for treating oral ulcer, can be used for remaining a thin precipitate after surface tissues of unhealed chronic wounds are solidified and serve as a barrier of organic substances, so that the ulcer is prevented from being further stimulated by substances in an oral cavity in the natural healing process to cause pain, and is effectively prevented from subsequent bacterial infection, tasteless and good in treatment effect.

Description

Pharmaceutical composition for chronic wound healing and application thereof
Technical Field
The invention belongs to the technical field of medical products, and particularly relates to a pharmaceutical composition for chronic wound healing and application thereof.
Background
Canker sores are an ulcerative loss condition that occurs in the mucous membranes of the mouth, often in the inner lip, tongue, soft palate, etc., where the mucous membranes lack a cornified layer or are poorly cornified. The fester necrosis part of the oral ulcer can leave yellow and white fester with a clear diameter of 2-5 mm on the surface of an organ, the fester edge can be hardened to a certain degree, and an erythema area appears around the fester edge, and the pathological change degree of the erythema area depends on the degree of secondary bacterial infection. The stomatocace has severe pain and obvious local burning pain, and causes great inconvenience to diet, speaking and daily life of patients when the stomatocace is serious; and is accompanied with symptoms such as chronic throat, halitosis, nausea, dysphoria, lymphadenectasis, etc. Canker sores are thought to be caused by viruses, and in some cases, genetics, body hormonal changes, and gastrointestinal imperfections are also contributing factors to canker sores.
In the aspect of pharmaceutical dosage forms, the main treatment modes of domestic oral ulcer at present comprise two types: one type is topical treatment, including topical tablets, powders, mouthwashes, sprays, topical gels, films, sprays, and the like; one is systemic medication, which mainly comprises oral preparations, capsules and the like. The medicine for systemic administration has slow release of the medicine effect and poor pertinence, and the long-term use of the medicine can more or less affect other organs of the human body. The tablet in the local medicine is hard, the mechanical stimulation to the wound surface is large when the tablet is applied, meanwhile, the film is difficult to be applied according to the size of ulcer, and the tablet is easy to be touched by the tongue to fall off; most of the powder and the powder spray are prepared from medicinal powder and the like, so the powder and the powder have poor taste, a protective layer is not easy to form at ulcer parts, the administration dosage at different parts is difficult to be uniform, and the treatment effect is poor; the gargle has low drug concentration, short residence time in oral cavity and low drug effect generation efficiency.
In terms of the pharmaceutical ingredients of the preparation for oral ulcer, CN 112826923a discloses a composition for oral ulcer, an oral ulcer film and a preparation method thereof. The composition comprises hyaluronic acid or its salt, ectoin, lidocaine, iodine, recombinant human epidermal growth factor, vitamin C and vitamin B2 as main ingredients. The composition is effective in relieving pain, resisting inflammation, and promoting healing. CN101444527A discloses a film agent for oral ulcer, which comprises macromolecular substances, is not added with antibacterial and anti-inflammatory substances, has no antibacterial and anti-inflammatory effects and has poor curative effect. CN101317917A discloses a buccal tablet for treating oral ulcer, which contains the main ingredients of traditional Chinese medicine and hormone, and has drug resistance and dependence after long-term use, and the buccal tablet has low administration concentration at the oral ulcer part and low drug effect generation efficiency. CN102579702A discloses a pharmaceutical composition for treating oral ulcer, the active ingredients of the pharmaceutical composition are antibacterial agent, anti-inflammatory ingredient and bee product, which can effectively relieve the symptoms and pain of oral ulcer in a short time and rapidly promote the healing of oral ulcer, but the antibacterial agent selected in the patent is silver ion or nano silver, which is not only expensive, but also has a certain risk of drug safety. CN1582172A discloses a method for treating canker sore by using oral patch to accelerate healing and relieve pain, firstly, the effective components of the oral patch are bactericide (penicillin and amoxicillin) and licorice extract, but the oral patch mainly limits local flow of saliva and needs at least 30min to apply the medicine on canker sore, and needs at least 2 hours per day, said method has the problems of low medicine administration efficiency, long application time, causing discomfort for people and easy falling off for general people.
Canker sores are caused by non-healing chronic wounds, primarily manifested as delayed healing of necrotic tissue, causing it to become a reservoir for bacterial growth, and are a major factor in promoting inflammation and cell migration. Conventional methods of treating chronic wounds are debridement, including autolytic, enzymatic, mechanical, and surgical procedures, but these conventional debridement treatments do not provide a good cure for the chronic wound, thereby causing subsequent discomfort and therapeutic distress to the patient and the physician.
Disclosure of Invention
In order to overcome the above-mentioned disadvantages of the prior art, an object of the present invention is to provide a pharmaceutical composition for chronic wound healing, which can be used for treating canker sores, can solidify and leave a thin layer of precipitate on the superficial tissues of unhealed chronic wounds, and can be used as a barrier for organic substances, so as to prevent the canker sores from being further stimulated by substances in the oral cavity during the natural healing process, and can effectively prevent subsequent bacterial infection.
The invention also aims to provide application of the pharmaceutical composition for chronic wound healing.
In order to achieve one of the purposes, the invention adopts the following technical scheme:
the pharmaceutical composition for treating oral ulcer comprises, by mass, 25-35% of sulfuric acid, 30-55% of hydroxybenzene sulfonic acid, and the balance of water.
Further, the composition also comprises 0.1-1% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt in percentage by mass.
Further, the coating also comprises 1-5% of a thickening agent in percentage by mass.
Further, the thickening agent is one or a composition of more than two of medical cellulose, colloidal silica, silica gel, fumed silica and liquid silica gel.
Further, the thickener comprises one or two of colloidal silica and cellulose.
In order to achieve the second purpose, the invention adopts the following technical scheme:
the invention provides application of a pharmaceutical composition for chronic wound healing, which is used for preparing a medicament for treating oral ulcer.
Further, the dosage form of the medicament for treating the oral ulcer is one of a liquid preparation, a gel preparation and a paste preparation.
Further, the viscosity of the medicine for treating the oral ulcer is 50-100000 cPs, and the acidity of the medicine for treating the oral ulcer is 7-9.5 mM/g.
Compared with the prior art, the invention has the following beneficial effects:
(1) the invention provides a pharmaceutical composition for chronic wound healing, wherein sulfuric acid and hydroxybenzene sulfonic acid in the composition firstly play a role in cleaning wounds, can penetrate and dissolve necrotic tissues, prevent damage caused by destructive inflammatory immune reaction caused by the necrotic tissues and effectively prevent a body from starting the destructive inflammatory immune reaction; secondly, the water attached to microorganisms and oral mucosa in or near the wound can be absorbed subsequently, and the antibiotic-resistant bacteria and the bacteria in the persistent state are killed before the bacteria enter the dormant or inactive state; importantly, a thin layer of precipitate is left after superficial tissue of the unhealed chronic wound is solidified and serves as a barrier of organic substances, so that the ulcer is prevented from being stimulated by substances in the oral cavity in the natural healing process to cause pain, and subsequent bacterial infection is effectively prevented; the hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt in the composition is a medical dye and plays a role in coloring; the thickener in the composition mainly plays a role in film formation and thickening, and the preparation can be made into a liquid spray type or a paste coating type by adjusting the addition amount of the thickener.
(2) The invention provides the application of the pharmaceutical composition for curing the chronic wounds, which is tasteless, can be sprayed or coated on the chronic wounds of the dental ulcers, can be used for curing the dental ulcers and has good curative effect.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present application more clearly and completely understood, the technical solutions of the present application will be described below with reference to the embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present application and are not intended to limit the present application.
Example 1
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 25% of sulfuric acid, 55% of hydroxybenzenesulfonic acid, 0.1% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt and 19.9% of water in percentage by mass.
Example 2
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises, by mass, 35% of sulfuric acid, 30% of hydroxybenzenesulfonic acid, 1% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 1% of colloidal silicon dioxide, 4% of medical grade cellulose, and 29% of water.
Example 3
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 5% of colloidal silicon dioxide and 14.4% of water in percentage by mass.
Example 4
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 5% of medical grade cellulose and 14.4% of water in percentage by mass.
Example 5
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 1% of colloidal silica and 18.4% of water in percentage by mass.
Example 6
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 1% of medical grade cellulose and 18.4% of water in percentage by mass.
Example 7
The embodiment provides a pharmaceutical composition for chronic wound healing, which comprises 30% of sulfuric acid, 50% of hydroxybenzenesulfonic acid, 0.6% of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt, 1% of silica gel, 2% of fumed silica, 2% of liquid silica gel and 14.4% of water in percentage by mass.
The sulfuric acid and the hydroxybenzene sulfonic acid in the composition firstly play a role in cleaning wounds, can penetrate and dissolve necrotic tissues, prevent damage caused by destructive inflammatory immune reaction initiated by the necrotic tissues and effectively prevent a body from starting the destructive inflammatory immune reaction; secondly, the water attached to microorganisms and oral mucosa in or near the wound can be absorbed subsequently, and the antibiotic-resistant bacteria and the bacteria in the persistent state are killed before the bacteria enter the dormant or inactive state; importantly, a thin layer of precipitate is left after superficial tissue of the unhealed chronic wound is solidified and serves as a barrier of organic substances, so that the ulcer is prevented from being stimulated by substances in the oral cavity in the natural healing process to cause pain, and subsequent bacterial infection is effectively prevented; the hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt in the composition is a medical dye and plays a role in coloring; the thickener in the composition mainly plays a role in film formation and thickening, and the preparation can be made into a liquid spray type or a paste coating type by adjusting the addition amount of the thickener.
Example 8
The embodiment provides an application of a pharmaceutical composition for chronic wound healing, the pharmaceutical composition for chronic wound healing is used for preparing a pharmaceutical preparation for treating dental ulcer, the viscosity of the pharmaceutical preparation is 50-100000 cPs, the acidity of the preparation is 7-9.5 mM/g, the density of the preparation can be properly adjusted according to needs, the preparation can be made into a liquid spray type or a paste coating type for application by adjusting the addition amount of a thickening agent, and the application can be specifically determined according to the selection and the adaptability of a patient.
The application method of the pharmaceutical preparation comprises the step of spraying or coating the pharmaceutical preparation on chronic wounds of canker sores, the preparation can generate stabbing pain at the wounds, no feeling is generated after about 15 seconds, then the skin can generate a protective film through self-healing of the surface layer of a human body, the protective film can inhibit the pain after the protective film is formed, and therefore the pain time is shortened. The pharmacological action of the medicinal preparation is that the medicinal preparation firstly plays a role in cleaning wounds, can penetrate and dissolve necrotic tissues, prevents damage caused by destructive inflammatory immune reaction initiated by the necrotic tissues and effectively prevents a body from starting the destructive inflammatory immune reaction; secondly, the water attached to microorganisms and oral mucosa in or near the wound can be absorbed subsequently, and the antibiotic-resistant bacteria and the bacteria in the persistent state are killed before the bacteria enter the dormant or inactive state; importantly, a thin layer of precipitate is left on the surface tissue of the unhealed chronic wound in a coagulation mode and serves as a barrier of organic substances, so that the ulcer is prevented from being stimulated by substances in the oral cavity in the natural healing process to cause pain, and subsequent bacterial infection is effectively prevented.
The above embodiments are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited thereby, and any insubstantial changes and substitutions made by those skilled in the art based on the present invention are within the protection scope of the present invention.

Claims (8)

1. The pharmaceutical composition for treating the chronic wound is characterized by comprising, by mass, 25-35% of sulfuric acid, 30-55% of hydroxybenzene sulfonic acid and the balance of water.
2. The pharmaceutical composition for chronic wound healing according to claim 1, further comprising 0.1 to 1% by mass of 6-hydroxy-5- [ (2-methoxy-5-methyl-4-sulfophenyl) azo ] -2-naphthalenesulfonic acid disodium salt.
3. The pharmaceutical composition for chronic wound healing according to claim 1, further comprising 1-5% by mass of a thickening agent.
4. The pharmaceutical composition for chronic wound healing according to claim 1, wherein the thickening agent is one or a combination of two or more of medical grade cellulose, colloidal silica, silica gel, fumed silica, liquid silica gel.
5. A pharmaceutical composition for chronic wound healing according to claim 4, wherein said thickening agent comprises colloidal silica and medical grade cellulose.
6. The use of the pharmaceutical composition for chronic wound healing according to claims 1 to 5, wherein the pharmaceutical composition for chronic wound healing is used for preparing a medicament for treating oral ulcer.
7. The use of a pharmaceutical composition for chronic wound healing according to claim 6, wherein the medicament for treating oral ulcer is in a dosage form of one of liquid preparation, gel preparation and paste preparation.
8. The use of a pharmaceutical composition for chronic wound healing according to claim 6, wherein the medicament for treating oral ulcer has a viscosity of 50 to 100000cPs, and the acidity of the medicament for treating oral ulcer is 7 to 9.5 mM/g.
CN202210587089.0A 2022-05-26 2022-05-26 Pharmaceutical composition for chronic wound healing and application thereof Pending CN114984039A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210587089.0A CN114984039A (en) 2022-05-26 2022-05-26 Pharmaceutical composition for chronic wound healing and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210587089.0A CN114984039A (en) 2022-05-26 2022-05-26 Pharmaceutical composition for chronic wound healing and application thereof

Publications (1)

Publication Number Publication Date
CN114984039A true CN114984039A (en) 2022-09-02

Family

ID=83028780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210587089.0A Pending CN114984039A (en) 2022-05-26 2022-05-26 Pharmaceutical composition for chronic wound healing and application thereof

Country Status (1)

Country Link
CN (1) CN114984039A (en)

Similar Documents

Publication Publication Date Title
CA2899661A1 (en) Compositions and methods for treating surface wounds
CN108135972B (en) Application of mussel mucin product in treating and preventing melanin-related diseases
US20210000759A1 (en) Cannabinoid and menthol compositions and methods
CN108159024B (en) Sustained-release patch for treating oral ulcer and preparation method thereof
AU2002312416A1 (en) Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
EP3164139B1 (en) Topical compositions and methods for treating wounds
JP2010163451A (en) Oral patch including licorice root extract for treating ulcer
CN108210689A (en) A kind of canker sore film containing hyaluronic acid and preparation method thereof
US4708873A (en) Method of chemically debriding uncerated necrotic tissue
CN105125445A (en) Toothpaste composition
CN109481527B (en) Traditional Chinese medicine composition for preventing or treating oral diseases and application thereof
US20210220292A1 (en) Cannabinoid and anesthetic compositions and methods
CN110151786B (en) Application of nano carbon particles in preparation of medicine for treating oral ulcer and medicine
CN114984039A (en) Pharmaceutical composition for chronic wound healing and application thereof
CN102552734B (en) Gargle for treating dental ulcer
CN111803622A (en) Liquid repairing film for oral ulcer
CN111000871A (en) Oral cavity spray and preparation method thereof
CN111110831A (en) Ulcer paste and preparation method thereof
CN100356910C (en) Medicine composition for treating beriberi
CN111358927B (en) Pujiang medicinal composition and application thereof
CN114377054B (en) Use of cyclocarya paliurus leaves or extracts thereof in preparation of drugs or cosmetics for preventing and/or treating acne
RU2173155C1 (en) Wound-healing, anti-inflammatory and anti-infectious medicinal preparation
CN111329881A (en) Oral ulcer film and preparation method and application thereof
CN110652501A (en) Preparation method of propolis traditional Chinese medicine adhesive tablet with double-layer structure for oral cavity
WO2022218136A1 (en) Use of adenine in preparation of drug for treating diabetic ulcers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication